Genentech, Inc.

Seattle Genetics, Inc.

Other

University of Iowa Research Foundation

Immunogen, Inc.

Genetech, Inc.

Esoterix, Inc.

University of Turku

F. Hoffmann-La Roche Ag

Seagen Inc.

Mark X Sliwkowski

Thomas Pillow

Gregory T Stelzer

Mary Beth Gardiner

Paul Polakis

Allen J Ebens

Susan D Spencer

Robert L Cohen

Gabriele Maria Schaefer

Leonard G Presta

Camellia W Adams

Gail Lewis Phillips

Mark S Dennis

Peter Senter

Jagath Reddy Junutula

Svetlana Doronina

Brian E Toki

Xiaocheng Chen

Toni Beth Kline

Ralph H Schwall

James A Wells

Peter Scott Dragovich

Richard L Vandlen

BinQing Wei

Wayne J Fairbrother

Marcus D Ballinger

Jack Sadowsky

Jennifer T Jones

Mary E Gerritsen

Germaine G Fuh

Walter A Blattler

Sharon Erickson

Vincent Danial Fitzpatrick

Robert Akita

Frederic S Jacobson

Lauric Haber

Birgit Bossenmaier

Binqing Wei

Hans Koll

Peter D Senter

Svetlana O Doronina

Stephen M Kelsey

Vincent Daniel Fitzpatrick

Leanne Berry

Maija Hollmen

Klaus Elenius

Jeffrey A Kern

Thomas Harden Pillow

Vincent Danial Fizpatrick

Stephen Michael Kelsey

Gabriele Schaefer

Hans-Joachim Muller

Hans-joachim Müller

The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.

Pyrrolobenzodiazepine antibody drug conjugates and methods of use

The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

Anti-HER2 antibodies and immunoconjugates

The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.

Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepines

Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.

Isoform specific anti-HER4 antibodies

The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.

Anti-HER antibodies

Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)&#x2003;&#x2003;Iwhere one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

Antibody-drug conjugates and methods

Multispecific anti-HER antibodies

Chimeric heteromultimer adhesins that bind the ligand of natural heromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of the ErbB2 and ErbB3 and ErbB2 and ErbB4. The chimeric ErB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

ErbB2 and ErbB3 chimeric heteromultimer receptors

The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.

Combination therapy of her expressing tumors

The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)&#x2003;&#x2003;I

Growing community of inventors

San Carlos, CA, United States of America

Mark X Sliwkowski